EA201592238A1 - Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма - Google Patents

Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма

Info

Publication number
EA201592238A1
EA201592238A1 EA201592238A EA201592238A EA201592238A1 EA 201592238 A1 EA201592238 A1 EA 201592238A1 EA 201592238 A EA201592238 A EA 201592238A EA 201592238 A EA201592238 A EA 201592238A EA 201592238 A1 EA201592238 A1 EA 201592238A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pi3k
inhibitors
modulators
gamma
proteinkinase
Prior art date
Application number
EA201592238A
Other languages
English (en)
Other versions
EA029614B1 (ru
Inventor
Прашант Кашинат Бхавар
Сваруп Кумар Венката Сатья Ваккаланка
Говиндараджулу Бабу
Original Assignee
Ризен Фармасьютикалз Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ризен Фармасьютикалз Са filed Critical Ризен Фармасьютикалз Са
Publication of EA201592238A1 publication Critical patent/EA201592238A1/ru
Publication of EA029614B1 publication Critical patent/EA029614B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

В настоящем изобретении предложены новые соединения (I), подходящие в качестве модуляторов протеинкиназы PI3K, в частности модуляторов протеинкиназы PI3K дельта (δ) и/или гамма (γ). В настоящем изобретении также предложены способы получения модуляторов протеинкиназы PI3K, фармацевтические композиции, содержащие указанные модуляторы, и способы лечения, предотвращения и/или ослабления заболеваний или нарушений, опосредованных PI3K киназой, с применением указанных модуляторов.
EA201592238A 2013-07-02 2014-07-01 Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма EA029614B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2937CH2013 2013-07-02
IN5935CH2013 2013-12-18
PCT/IB2014/062775 WO2015001491A1 (en) 2013-07-02 2014-07-01 Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors

Publications (2)

Publication Number Publication Date
EA201592238A1 true EA201592238A1 (ru) 2016-05-31
EA029614B1 EA029614B1 (ru) 2018-04-30

Family

ID=51355578

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592238A EA029614B1 (ru) 2013-07-02 2014-07-01 Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма

Country Status (8)

Country Link
US (1) US11352359B2 (ru)
EP (1) EP3016955B1 (ru)
JP (1) JP6371838B2 (ru)
CN (2) CN111153905A (ru)
CA (1) CA2915418C (ru)
EA (1) EA029614B1 (ru)
ES (1) ES2672018T3 (ru)
WO (1) WO2015001491A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102382106A (zh) * 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
JP6557266B2 (ja) * 2014-06-27 2019-08-07 ライゼン・ファーマシューティカルズ・エスアー Ｐｉ３デルタ及びガンマタンパク質キナーゼの選択的二重阻害剤としての置換クロメン誘導体
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
US10882863B2 (en) 2016-05-13 2021-01-05 The Trustees Of Columbia University In The City Of New York Compounds for reducing c-Myc in c-Myc overexpressing cancers background
JOP20190052A1 (ar) 2016-09-22 2019-03-21 Astrazeneca Ab 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
SG10201911076QA (en) * 2016-12-16 2020-01-30 Cystic Fibrosis Found Bycyclic heteroaryl derivatives as cftr potentiators
EP3672970A1 (en) 2017-08-22 2020-07-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
JP7199502B2 (ja) 2018-07-06 2023-01-05 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
US11098027B2 (en) 2018-07-06 2021-08-24 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CN111269231B (zh) * 2018-12-04 2023-06-09 安徽中科拓苒药物科学研究有限公司 一种选择性PI3Kδ抑制剂及其用途
EP3964512A4 (en) * 2019-06-27 2022-08-10 Hangzhou Healzen Therapeutics Co., Ltd. CASEINKINASE-1-EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND ITS USE
WO2021119669A1 (en) * 2019-12-12 2021-06-17 Loma Linda University Pathology Medical Group, Inc. Methods and compositions for treatment of acute myeloid leukemia
CN114591335B (zh) * 2021-03-29 2023-06-27 浙江大学 吲唑类化合物及其制备方法和应用
WO2023183470A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
CN116987085A (zh) * 2022-04-26 2023-11-03 安徽中科拓苒药物科学研究有限公司 一种PI3Kδ抑制剂及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1278748E (pt) 2000-04-25 2011-03-31 Icos Corp Inibidores de delta 3-cinase humana de fosfatidilinositol
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
KR20150038395A (ko) * 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
AU2009204483B2 (en) * 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US20110269779A1 (en) * 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
EA036876B1 (ru) 2009-11-05 2020-12-30 Ризен Фармасьютикалз С.А. Ингибиторы pi3k киназы
WO2012118978A1 (en) 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
SI2705029T1 (sl) * 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S.A. Nove spojine kot modulatori protein-kinaz
WO2013029116A1 (en) 2011-08-31 2013-03-07 Monash University Method for predicting treatment responsiveness
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
RU2012112128A (ru) 2012-03-29 2013-10-10 Холин Максим Николаевич ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
JP6584952B2 (ja) 2012-11-01 2019-10-02 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療

Also Published As

Publication number Publication date
CN111153905A (zh) 2020-05-15
US11352359B2 (en) 2022-06-07
EA029614B1 (ru) 2018-04-30
CN105431437B (zh) 2020-03-10
ES2672018T3 (es) 2018-06-12
EP3016955A1 (en) 2016-05-11
JP2016523892A (ja) 2016-08-12
CA2915418C (en) 2022-05-03
US20160207929A1 (en) 2016-07-21
EP3016955B1 (en) 2018-03-07
JP6371838B2 (ja) 2018-08-08
CN105431437A (zh) 2016-03-23
WO2015001491A1 (en) 2015-01-08
CA2915418A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
EA201592238A1 (ru) Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма
AU2018236800B2 (en) DNA-PK inhibitors
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
EA201792047A1 (ru) Новые соединения
MX367918B (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
CL2015003731A1 (es) Inhibidores de bromodominios
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201592113A1 (ru) Двойные селективные ингибиторы pi3-киназ дельта и гамма
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
EA201591420A1 (ru) Гетероарильные соединения и их применение
SG10201908558WA (en) Biaryl Compounds Useful For The Treatment Of Human Diseases In Oncology, Neurology And Immunology
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
PH12015501053A1 (en) Oxazolidin-2-one-pyrimidine derivatives
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы